Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Debt / NOTE 0.599% 8/0
-
Market price (% of par)
-
101.5%
-
Total 13F principal
-
$400,691,200
-
Principal change
-
+$400,691,200
-
Total reported market value
-
$406,783,596
-
Number of holders
-
39
-
Value change
-
+$406,783,596
-
Number of buys
-
39
Institutional Holders of BIOMARIN PHARMACEUTICAL INC - NOTE 0.599% 8/0 as of Q3 2017
As of 30 Sep 2017,
BIOMARIN PHARMACEUTICAL INC - NOTE 0.599% 8/0 was held by
39 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$400,691,200
in principal (par value) of the bond.
The largest 10 bondholders included
Linden Advisors LP, SILVERBACK ASSET MANAGEMENT LLC, Allianz Asset Management GmbH, ROYAL BANK OF CANADA, ADVENT CAPITAL MANAGEMENT /DE/, Polar Asset Management Partners Inc., JPMORGAN CHASE & CO, STATE STREET CORP, BAKER BROS. ADVISORS LP, and LAZARD ASSET MANAGEMENT LLC.
This page lists
39
institutional bondholders reporting positions
for the Q3 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.